Allakos Inc. (ALLK)
After hours:
- Motley Fool
Why Allakos Stock Was Heating Up Today
Although Allakos reported a net loss of $43 million in the fourth quarter of 2022, investors were more concerned with the progress of the company's clinical pipeline. More specifically, Allakos reaffirmed today that it expects to report trial results from a pair of ongoing mid-stage studies for its lead compound, lirentelimab, in the second half of 2023. The monoclonal antibody is presently in a phase 2 trial as a treatment for atopic dermatitis and a phase 2b trial for chronic spontaneous urticaria (hives).
- GlobeNewswire
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab (AK002) and AK006. Recent Allakos Events Initiated a Phase 2b randomized, double-blind, placebo-cont
- Simply Wall St.
Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
How far off is Allakos Inc. ( NASDAQ:ALLK ) from its intrinsic value? Using the most recent financial data, we'll take...
